Diabetic neuropathies are the most common chronic complications of diabetes. This heterogeneous group of diseases affects different parts of the nervous system and has different clinical manifestations. Due to the lack of treatments aimed at repairing damaged nerves, prevention is a key component of the treatment of diabetic neuropathy. The purpose of the study was to assess the psychoemotional status of patients with type 2 diabetes mellitus and chronic gastritis and its relationship to serum ghrelin and magnesium ions. Material and methods. 77 patients were examined on the basis of the endocrinology department of Municipal Non-Commercial Enterprise "Transcarpathian Regional Clinical Hospital named after Andriy Novak". Their average age was 59.7 ± 4.1 years. This study was conducted with 41 (53.2%) women and 36 (46.8%) men. All patients were diagnosed with type 2 diabetes mellitus and chronic gastritis. All patients were surveyed using the following questionnaires: Quality of Life Questionnaire - Diabetic Neuropathy version (QOL-DN), Peripheral Neuropathy Quality-of-Life Instrument-97 (PN-QOL-97) and Pittsburgh Sleep Quality Index (PSQI). All patients underwent an objective examination by a podiatrist to assess the sensitivity and pulsation in the arteries of the feet. Serum ghrelin levels were determined by enzyme-linked immunosorbent assay using the Human Ghrelin ELISA Kit from RayBiotech No. 1.03930005306. Determination of serum magnesium levels was performed by colorimetry, the units are mmol / l. The normal value of magnesium levels was considered to be 0.66-1.07 mmol / l. All patients received combination therapy. Results and discussion. According to our study, the use of iDPP-4 in the treatment of type 2 diabetes and chronic gastritis not only promotes better glycemic control, but also to some extent improves the psychological state of patients with type 2 diabetes and hC, on the background of adequate hypoglycemic therapy and correction of magnesium deficiency using alpha-lipoic acid and B vitamins. After treatment, the average level of magnesium in the blood was from 0.31 ± 0.12 mmol / l in patients with type 2 diabetes and chronic gastritis increased to 0.68 ± 0.17 mmol / l (p <0.05). As for quality of life, significantly more improvement was obtained in group I, although the treatment of hypomagnesemia and diabetic polyneuropathy was carried out in one scheme, the only indicator that became different significantly after treatment with IDPP-4 was ghrelin, because there is an opinion about stress-protective effects of ghrelin. it can be assumed that its approximation to the norm may contribute to a better course of the disease. Conclusion. Combination therapy with hypoglycemic agents, including i-DPP-4, alpha-lipoic acid, B vitamins, magnesium antistress in patients with type 2 diabetes and chronic gastritis led to an improvement in the psychological state against the background of normal blood sugar levels

Keywords: type 2 diabetes mellitus, chronic gastritis, neuropathy, ghrelin, magnesium

Full text: PDF (Ukr) 311K

1. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes care. 2017; 40(1): 136-154. https://doi.org/10.2337/dc16-2042
2. Juster-Switlyk K, Smith AG. Updates in diabetic peripheral neuropathy. F1000Res. 2016 Apr 25; 5: F1000 Faculty Rev-738. https://doi.org/10.12688/f1000research.7898.1
3. Fisher L, Hessler DM, Polonsky WH, Mullan J. When is diabetes distress clinically meaningful?: establishing cut points for the Diabetes Distress Scale. Diabetes care. 2012; 35(2): 259-264. https://doi.org/10.2337/dc11-1572
4. Joy SS, George TP, Siddiqui K. Low magnesium level as an indicator of poor glycemic control in type 2 diabetic patients with complications. Diabetes Metabc Synd. 2019; 13(2): 1303-1307. https://doi.org/10.1016/j.dsx.2019.02.001
5. Zhang Y, Li Q, Xin Y, Lv W, Ge C. Association between serum magnesium and common complications of diabetes mellitus. Technol Health Care. 2018; 26(S1): 379-387. https://doi.org/10.3233/THC-174702
6. Abizaid A. Stress and obesity: The ghrelin connection. J Neuroendocrinol. 2019; 31(7): e12693. https://doi.org/10.1111/jne.12693
7. Bhardwaj A, Hyanki D, Srivastav R. A Study of Magnesium Supplementation on Amplitudes of Sensory and Motor Nerves in Patients of Diabetic Neuropathy. International Journal of Physiology 2019; 7(3): 58-63.
8. Li Y, Yue J, Yang C. Unraveling the role of Mg++ in osteoarthritis. Life sciences. 2016; 147: 24-29. https://doi.org/10.1016/j.lfs.2016.01.029
9. Kirkland AE, Sarlo GL, Holton KF. The role of magnesium in neurological disorders. Nutrients. 2018; 10(6): 730. https://doi.org/10.3390/nu10060730
10. Cambray S, Ibarz M, Bermudez-Lopez M, Marti-Antonio M, Bozic M, Fernandez E, et al. Magnesium Levels Modify the Effect of Lipid Parameters on Carotid Intima Media Thickness. Nutrients. 2020; 12(9): 2631. https://doi.org/10.3390/nu12092631